Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T-DM1)

Br J Dermatol. 2022 Nov;187(5):e168. doi: 10.1111/bjd.21654. Epub 2022 May 28.

Authors

Annika Belzer¹, Andrea Silber², Saral Mehra³, Syed Gilani⁴, Jonathan S Leventhal⁵

Affiliations

¹ Yale School of Medicine, New Haven, CT, USA.
² Department of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
³ Department of Otolaryngology, Yale School of Medicine, New Haven, CT, USA.
⁴ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
⁵ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.

PMID: 35633104
DOI: 10.1111/bjd.21654

No abstract available

MeSH terms

Ado-Trastuzumab Emtansine / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms* / drug therapy
Female
Hemangioma* / drug therapy
Humans
Receptor, ErbB-2

Substances

Ado-Trastuzumab Emtansine
Antineoplastic Agents, Immunological
Antibodies, Monoclonal, Humanized
Receptor, ErbB-2